AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04282070
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maximum 6 cycles for combined therapy.
Trial: NCT00216775
Drug: interferon-alfa-2b and ribavirin
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01146951
Drug: Rufinamide (E2080)
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
Trial: NCT04167137
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
Trial: NCT00142402
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01329289
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
Trial: NCT01329289
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
Trial: NCT03181841
Drug: PF-06412562
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blind oral intake of single doses of the aforementioned drug or placebo
Trial: NCT03164018
Drug: Fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
Trial: NCT02097485
Drug: Abametapir Lotion 0.74% w/w
DrugBank: Abametapir (DB11932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Trial: NCT02097485
Drug: Vehicle Lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
Trial: NCT03836352
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion (q3w)
Trial: NCT02126670
Drug: ACT01
RxNorm normalized name: Immunoglobulin g1, anti-(human platetet glycoprotein vi) fab fragment (humanized monoclonal act017 .gamma.1-chain), disulfide with humanized monoclonal act017 .kappa.-chain
DrugBank: Glenzocimab (DB16175)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00989404
Drug: Zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotahaler placebo 10mg BID 5 days
Trial: NCT00989404
Drug: Zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotahaler Zanamivir 10mg BID 5 days
Trial: NCT00989404
Drug: Zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diskhaler Zanamivir 10mg BID 5 days
Trial: NCT01481909
Drug: Rupatadin
RxNorm normalized name: Rupatadina
DrugBank: Rupatadine (DB11614)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg, 28 days over 60 days
Trial: NCT00360048
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04718584
Drug: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
Trial: NCT00665678
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment for three months with paroxetine
Trial: NCT00003595
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003595
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01051115
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
Trial: NCT00505804
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
Trial: NCT00505804
Drug: haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
Trial: NCT01768338
Drug: Ofatumumab combined with SB-485232
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab with escalating doses of SB-485232
Trial: NCT01708707
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days.
Trial: NCT01708707
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
Trial: NCT00067821
Drug: 2-Flourodeoxyglucose
RxNorm normalized name: fluorodeoxyglucose F18
DrugBank: Fludeoxyglucose (DB15107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02485548
Drug: Raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IMRT and concurrent raltitrexed and cisplatin
Trial: NCT02485548
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive IMRT and concurrent 5-Fu and cisplatin
Trial: NCT02485548
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive concurrent cisplatin.
Trial: NCT00424346
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03182413
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03305757
Drug: Artiss
RxNorm normalized name: Artiss
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of ARTISS Glue to skin flaps after mastectomy
Trial: NCT01874119
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Trial: NCT02671955
Drug: JNJ-61610588
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
Trial: NCT01141127
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of two dosage regimen of Tranexamic Acid
Trial: NCT00647257
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Trial: NCT01902537
Drug: Prucalopride; observational study
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
Trial: NCT00000248
Drug: Pergolide
RxNorm normalized name: Pergolide
DrugBank: Pergolide (DB01186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02407314
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
Trial: NCT02407314
Drug: Aspirin + Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
Trial: NCT01109069
Drug: PCI-32765
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose based on parent protocol
Trial: NCT03203590
Drug: Oral Navelbine + Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
Trial: NCT03203590
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
Trial: NCT04036929
Drug: Estrogen-bazedoxifene
RxNorm normalized name: bazedoxifene / estrogens, conjugated (USP)
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
Trial: NCT01753167
Drug: MCMV3068A
RxNorm normalized name: MCMV3068A
DrugBank: MCMV3068A (DB17764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Trial: NCT01431963
Drug: Lamictal
RxNorm normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No comparison.
Trial: NCT00306540
Drug: Quetiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral flexible dose
Trial: NCT00306540
Drug: quetiapine fumarate placebo
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral 0 mg
Trial: NCT00180843
Drug: salbutamol + ipratropium bromide nebules
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02089126
Drug: Gemigliptin/Glimepiride combination
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00568451
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
Trial: NCT00568451
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
Trial: NCT00568451
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
Trial: NCT02127151
Drug: BMN 673
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
Trial: NCT03035617
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
Trial: NCT03330561
Drug: PRS-343
RxNorm normalized name: IMMUNOGLOBULIN G4 (228-PROLINE, 234-ALANINE, 235-ALANINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL PRS-343 .GAMMA.4-CHAIN) FUSION PROTEIN PEPTIDE (SYNTHETIC 15-AMINO ACID LINKER) FUSION PROTEIN WITH LIPOCALIN 2 (HUMAN MU
DrugBank: Cinrebafusp alfa (DB18402)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS-343
Trial: NCT04604756
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of losartan (50 mg) (oral)
Trial: NCT01400477
Drug: DMXB-A-SR
RxNorm normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
Trial: NCT03246451
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000-2000 mg in 14 days
Trial: NCT03246451
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 mg/ml saline infusion during experimental days
Trial: NCT03246451
Drug: Exendin (9-39)
RxNorm normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of GLP-1 receptor antagonist used as a tool during experimental days
Trial: NCT02137252
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02137252
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01601418
Drug: YF476
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
Trial: NCT01874028
Drug: trientine dihydrochloride
RxNorm normalized name: trientine dihydrochloride 300 MG Oral Capsule
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
Trial: NCT02066844
Drug: Celestone
RxNorm normalized name: Celestone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2cc
Trial: NCT02066844
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5cc
Trial: NCT02101944
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02101944
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03036826
Drug: Piperacillin/tazobactam
RxNorm normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiinfective therapy with Piperacillin/Tazobactam within routine care
Trial: NCT03036826
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiinfective therapy with Meropenem within routine care
Trial: NCT04499989
Drug: INH
RxNorm normalized name: INH
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
Trial: NCT01753167
Drug: MCMV5322A
RxNorm normalized name: MCMV5322A
DrugBank: MCMV5322A (DB17763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Trial: NCT01900743
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
Trial: NCT00861471
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days.
Trial: NCT00861471
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.
Trial: NCT02157077
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Injection
Trial: NCT01007721
Drug: BI 67100 ED 25 mg
RxNorm normalized name: Ed-APAP
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of BI 671800 ED 25 mg
Trial: NCT01007721
Drug: BI 671800 ED placebo
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)
Trial: NCT01007721
Drug: montelukast placebo tablet
RxNorm normalized name: placebo Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Trial: NCT00968877
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.